{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PI4KB", "antiviral", "edible plant", "enterovirus", "picornavirus", "virus"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37112883", "DateCompleted": {"Year": "2023", "Month": "05", "Day": "01"}, "DateRevised": {"Year": "2023", "Month": "05", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "03", "Day": "31"}], "Language": ["eng"], "ELocationID": ["903", "10.3390/v15040903"], "Journal": {"ISSN": "1999-4915", "JournalIssue": {"Volume": "15", "Issue": "4", "PubDate": {"Year": "2023", "Month": "Mar", "Day": "31"}}, "Title": "Viruses", "ISOAbbreviation": "Viruses"}, "ArticleTitle": "Characterization of Anti-Poliovirus Compounds Isolated from Edible Plants.", "Abstract": {"AbstractText": ["Poliovirus (PV) is the causative agent of poliomyelitis and is a target of the global eradication programs of the World Health Organization (WHO). After eradication of type 2 and 3 wild-type PVs, vaccine-derived PV remains a substantial threat against the eradication as well as type 1 wild-type PV. Antivirals could serve as an effective means to suppress the outbreak; however, no anti-PV drugs have been approved at present. Here, we screened for effective anti-PV compounds in a library of edible plant extracts (a total of 6032 extracts). We found anti-PV activity in the extracts of seven different plant species. We isolated chrysophanol and vanicoside B (VCB) as the identities of the anti-PV activities of the extracts of <i>Rheum rhaponticum</i> and <i>Fallopia sachalinensis</i>, respectively. VCB targeted the host PI4KB/OSBP pathway for its anti-PV activity (EC<sub>50</sub> = 9.2 \u03bcM) with an inhibitory effect on in vitro PI4KB activity (IC<sub>50</sub> = 5.0 \u03bcM). This work offers new insights into the anti-PV activity in edible plants that may serve as potent antivirals for PV infection."]}, "AuthorList": [{"Identifier": ["0000-0002-3314-6626"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi 208-0011, Tokyo, Japan."}], "LastName": "Arita", "ForeName": "Minetaro", "Initials": "M"}, {"Identifier": ["0000-0002-6302-4507"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition, 1-2 Hachimandai, Tsukuba 305-0843, Ibaraki, Japan."}], "LastName": "Fuchino", "ForeName": "Hiroyuki", "Initials": "H"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Viruses", "NlmUniqueID": "101509722", "ISSNLinking": "1999-4915"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}], "SupplMeshList": ["Fallopia sachalinensis"], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Plants, Edible"}, {"QualifierName": [], "DescriptorName": "Virus Replication"}, {"QualifierName": [], "DescriptorName": "Poliovirus"}, {"QualifierName": [], "DescriptorName": "Poliomyelitis"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antiviral Agents"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Kitamura N., Semler B.L., Rothberg P.G., Larsen G.R., Adler C.J., Dorner A.J., Emini E.A., Hanecak R., Lee J.J., van der Werf S., et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981;291:547\u2013553. doi: 10.1038/291547a0.", "ArticleIdList": ["10.1038/291547a0", "6264310"]}, {"Citation": "Macklin G.R., O\u2019Reilly K.M., Grassly N.C., Edmunds W.J., Mach O., Santhana Gopala Krishnan R., Voorman A., Vertefeuille J.F., Abdelwahab J., Gumede N., et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401\u2013405. doi: 10.1126/science.aba1238.", "ArticleIdList": ["10.1126/science.aba1238", "32193361"]}, {"Citation": "WHO.  [(accessed on 27 February 2023)].  Available online:  https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/"}, {"Citation": "Link-Gelles R., Lutterloh E., Schnabel Ruppert P., Backenson P.B., St George K., Rosenberg E.S., Anderson B.J., Fuschino M., Popowich M., Punjabi C., et al. Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater\u2014New York, June-August 2022. MMWR Morb. Mortal Wkly. Rep. 2022;71:1065\u20131068. doi: 10.15585/mmwr.mm7133e2.", "ArticleIdList": ["10.15585/mmwr.mm7133e2", "PMC9400530", "35980868"]}, {"Citation": "Klapsa D., Wilton T., Zealand A., Bujaki E., Saxentoff E., Troman C., Shaw A.G., Tedcastle A., Majumdar M., Mate R., et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet. 2022;400:1531\u20131538. doi: 10.1016/S0140-6736(22)01804-9.", "ArticleIdList": ["10.1016/S0140-6736(22)01804-9", "PMC9627700", "36243024"]}, {"Citation": "Anis E., Kopel E., Singer S.R., Kaliner E., Moerman L., Moran-Gilad J., Sofer D., Manor Y., Shulman L.M., Mendelson E., et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Eurosurveillance. 2013;18:20586. doi: 10.2807/1560-7917.ES2013.18.38.20586.", "ArticleIdList": ["10.2807/1560-7917.ES2013.18.38.20586", "24084337"]}, {"Citation": "Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., Weiner A.J., Bandyopadhyay A.S., Van Damme P., De Coster I., et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020;27:736\u2013751.e8. doi: 10.1016/j.chom.2020.04.003.", "ArticleIdList": ["10.1016/j.chom.2020.04.003", "PMC7566161", "32330425"]}, {"Citation": "Bandyopadhyay A.S., Zipursky S. A novel tool to eradicate an ancient scourge: The novel oral polio vaccine type 2 story. Lancet Infect. Dis. 2023;23:e67\u2013e71. doi: 10.1016/S1473-3099(22)00582-5.", "ArticleIdList": ["10.1016/S1473-3099(22)00582-5", "36162417"]}, {"Citation": "Collett M.S., Neyts J., Modlin J.F. A case for developing antiviral drugs against polio. Antiviral Res. 2008;79:179\u2013187. doi: 10.1016/j.antiviral.2008.04.002.", "ArticleIdList": ["10.1016/j.antiviral.2008.04.002", "18513807"]}, {"Citation": "Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication, National Research Council . Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. The National Academies Press; Washington, DC, USA: 2006."}, {"Citation": "De Palma A.M., Vliegen I., De Clercq E., Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008;28:823\u2013884. doi: 10.1002/med.20125.", "ArticleIdList": ["10.1002/med.20125", "18381747"]}, {"Citation": "Maynell L.A., Kirkegaard K., Klymkowsky M.W. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 1992;66:1985\u20131994. doi: 10.1128/jvi.66.4.1985-1994.1992.", "ArticleIdList": ["10.1128/jvi.66.4.1985-1994.1992", "PMC288987", "1312615"]}, {"Citation": "Irurzun A., Perez L., Carrasco L. Involvement of membrane traffic in the replication of poliovirus genomes: Effects of brefeldin A. Virology. 1992;191:166\u2013175. doi: 10.1016/0042-6822(92)90178-R.", "ArticleIdList": ["10.1016/0042-6822(92)90178-R", "1329315"]}, {"Citation": "Bordeleau M.E., Mori A., Oberer M., Lindqvist L., Chard L.S., Higa T., Belsham G.J., Wagner G., Tanaka J., Pelletier J. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2006;2:213\u2013220. doi: 10.1038/nchembio776.", "ArticleIdList": ["10.1038/nchembio776", "16532013"]}, {"Citation": "Geller R., Vignuzzi M., Andino R., Frydman J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 2007;21:195\u2013205. doi: 10.1101/gad.1505307.", "ArticleIdList": ["10.1101/gad.1505307", "PMC1770902", "17234885"]}, {"Citation": "Hoffmann H.H., Kunz A., Simon V.A., Palese P., Shaw M.L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc. Natl. Acad. Sci. USA. 2011;108:5777\u20135782. doi: 10.1073/pnas.1101143108.", "ArticleIdList": ["10.1073/pnas.1101143108", "PMC3078400", "21436031"]}, {"Citation": "Lee K., Kim D.E., Jang K.S., Kim S.J., Cho S., Kim C. Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion. Oncotarget. 2017;8:115315\u2013115325. doi: 10.18632/oncotarget.23258.", "ArticleIdList": ["10.18632/oncotarget.23258", "PMC5777774", "29383162"]}, {"Citation": "Zhang Z., Yang E., Hu C., Cheng H., Chen C.Y., Huang D., Wang R., Zhao Y., Rong L., Vignuzzi M., et al. Cell-Based High-Throughput Screening Assay Identifies 2\u2032,2\u2032-Difluoro-2\u2032-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent. ACS Infect. Dis. 2017;3:45\u201353. doi: 10.1021/acsinfecdis.6b00116.", "ArticleIdList": ["10.1021/acsinfecdis.6b00116", "PMC5754216", "27733043"]}, {"Citation": "Grollman A.P. Inhibitors of protein biosynthesis. V. Effects of emetine on protein and nucleic acid biosynthesis in HeLa cells. J. Biol. Chem. 1968;243:4089\u20134094. doi: 10.1016/S0021-9258(18)93283-7.", "ArticleIdList": ["10.1016/S0021-9258(18)93283-7", "4299101"]}, {"Citation": "Wikel J.H., Paget C.J., DeLong D.C., Nelson J.D., Wu C.Y., Paschal J.W., Dinner A., Templeton R.J., Chaney M.O., Jones N.D., et al. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J. Med. Chem. 1980;23:368\u2013372. doi: 10.1021/jm00178a004.", "ArticleIdList": ["10.1021/jm00178a004", "6247489"]}, {"Citation": "Heinz B.A., Vance L.M. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 1995;69:4189\u20134197. doi: 10.1128/jvi.69.7.4189-4197.1995.", "ArticleIdList": ["10.1128/jvi.69.7.4189-4197.1995", "PMC189156", "7769678"]}, {"Citation": "Hsu N.Y., Ilnytska O., Belov G., Santiana M., Chen Y.H., Takvorian P.M., Pau C., van der Schaar H., Kaushik-Basu N., Balla T., et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141:799\u2013811. doi: 10.1016/j.cell.2010.03.050.", "ArticleIdList": ["10.1016/j.cell.2010.03.050", "PMC2982146", "20510927"]}, {"Citation": "Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 2011;85:2364\u20132372. doi: 10.1128/JVI.02249-10.", "ArticleIdList": ["10.1128/JVI.02249-10", "PMC3067798", "21177810"]}, {"Citation": "Delang L., Paeshuyse J., Neyts J. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem. Pharmacol. 2012;84:1400\u20131408. doi: 10.1016/j.bcp.2012.07.034.", "ArticleIdList": ["10.1016/j.bcp.2012.07.034", "PMC7111036", "22885339"]}, {"Citation": "MacLeod A.M., Mitchell D.R., Palmer N.J., Van de Poel H., Conrath K., Andrews M., Leyssen P., Neyts J. Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. ACS Med. Chem. Lett. 2013;4:585\u2013589. doi: 10.1021/ml400095m.", "ArticleIdList": ["10.1021/ml400095m", "PMC4030314", "24900715"]}, {"Citation": "Mejdrova I., Chalupska D., Kogler M., Sala M., Plackova P., Baumlova A., Hrebabecky H., Prochazkova E., Dejmek M., Guillon R., et al. Highly Selective Phosphatidylinositol 4-Kinase IIIbeta Inhibitors and Structural Insight into Their Mode of Action. J. Med. Chem. 2015;58:3767\u20133793. doi: 10.1021/acs.jmedchem.5b00499.", "ArticleIdList": ["10.1021/acs.jmedchem.5b00499", "25897704"]}, {"Citation": "Arita M., Dobrikov G., Purstinger G., Galabov A.S. Allosteric Regulation of Phosphatidylinositol 4-Kinase III Beta by an Antipicornavirus Compound MDL-860. ACS Infect. Dis. 2017;3:585\u2013594. doi: 10.1021/acsinfecdis.7b00053.", "ArticleIdList": ["10.1021/acsinfecdis.7b00053", "28605587"]}, {"Citation": "De Palma A.M., Thibaut H.J., van der Linden L., Lanke K., Heggermont W., Ireland S., Andrews R., Arimilli M., Altel T., De Clercq E., et al. Mutations in the non-structural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 2009;53:1850\u20131857. doi: 10.1128/AAC.00934-08.", "ArticleIdList": ["10.1128/AAC.00934-08", "PMC2681499", "19237651"]}, {"Citation": "Arita M., Takebe Y., Wakita T., Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and early stage of enterovirus 71 infection. J. Gen. Virol. 2010;91:2734\u20132744. doi: 10.1099/vir.0.023374-0.", "ArticleIdList": ["10.1099/vir.0.023374-0", "20660150"]}, {"Citation": "Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J. Virol. 2013;87:4252\u20134260. doi: 10.1128/JVI.03546-12.", "ArticleIdList": ["10.1128/JVI.03546-12", "PMC3624399", "23365445"]}, {"Citation": "Strating J.R., van der Linden L., Albulescu L., Bigay J., Arita M., Delang L., Leyssen P., van der Schaar H.M., Lanke K.H., Thibaut H.J., et al. Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein. Cell Rep. 2015;10:600\u2013615. doi: 10.1016/j.celrep.2014.12.054.", "ArticleIdList": ["10.1016/j.celrep.2014.12.054", "PMC4383725", "25640182"]}, {"Citation": "Albulescu L., Bigay J., Biswas B., Weber-Boyvat M., Dorobantu C.M., Delang L., van der Schaar H.M., Jung Y.S., Neyts J., Olkkonen V.M., et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017;140:37\u201344. doi: 10.1016/j.antiviral.2017.01.008.", "ArticleIdList": ["10.1016/j.antiviral.2017.01.008", "28088354"]}, {"Citation": "Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R., Shih S.R. An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 1999;341:929\u2013935. doi: 10.1056/NEJM199909233411301.", "ArticleIdList": ["10.1056/NEJM199909233411301", "10498487"]}, {"Citation": "Schuffenecker I., Mirand A., Josset L., Henquell C., Hecquet D., Pilorge L., Petitjean-Lecherbonnier J., Manoha C., Legoff J., Deback C., et al. Epidemiological and clinical characteristics of patients infected with enterovirus D68, France, July to December 2014. Eurosurveillance. 2016;21:30226. doi: 10.2807/1560-7917.ES.2016.21.19.30226.", "ArticleIdList": ["10.2807/1560-7917.ES.2016.21.19.30226", "27195770"]}, {"Citation": "Arita M., Fuchino H., Kawakami H., Ezaki M., Kawahara N. Characterization of a New Antienterovirus D68 Compound Purified from Avocado. ACS Infect. Dis. 2020;6:2291\u20132300. doi: 10.1021/acsinfecdis.0c00404.", "ArticleIdList": ["10.1021/acsinfecdis.0c00404", "32567833"]}, {"Citation": "Arita M., Bigay J. Poliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III beta/Oxysterol-Binding Protein Family I Pathway. ACS Infect. Dis. 2019;5:962\u2013973. doi: 10.1021/acsinfecdis.9b00038.", "ArticleIdList": ["10.1021/acsinfecdis.9b00038", "30919621"]}, {"Citation": "Arita M., Nagata N., Sata T., Miyamura T., Shimizu H. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. Pt 11J. Gen. Virol. 2006;87:3317\u20133327. doi: 10.1099/vir.0.82172-0.", "ArticleIdList": ["10.1099/vir.0.82172-0", "17030866"]}, {"Citation": "Baltera R.F., Jr., Tershak D.R. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J. Virol. 1989;63:4441\u20134444. doi: 10.1128/jvi.63.10.4441-4444.1989.", "ArticleIdList": ["10.1128/jvi.63.10.4441-4444.1989", "PMC251066", "2550675"]}, {"Citation": "Crotty S., Saleh M.C., Gitlin L., Beske O., Andino R. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J. Virol. 2004;78:3378\u20133386. doi: 10.1128/JVI.78.7.3378-3386.2004.", "ArticleIdList": ["10.1128/JVI.78.7.3378-3386.2004", "PMC371039", "15016860"]}, {"Citation": "Tanner E.J., Liu H.M., Oberste M.S., Pallansch M., Collett M.S., Kirkegaard K. Dominant drug targets suppress the emergence of antiviral resistance. eLife. 2014;3:e03830. doi: 10.7554/eLife.03830.", "ArticleIdList": ["10.7554/eLife.03830", "PMC4270081", "25365453"]}, {"Citation": "Mosser A.G., Sgro J.Y., Rueckert R.R. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J. Virol. 1994;68:8193\u20138201. doi: 10.1128/jvi.68.12.8193-8201.1994.", "ArticleIdList": ["10.1128/jvi.68.12.8193-8201.1994", "PMC237285", "7966611"]}, {"Citation": "Purstinger G., De Palma A.M., Zimmerhofer G., Huber S., Ladurner S., Neyts J. Synthesis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzonitriles. Bioorg. Med. Chem. Lett. 2008;18:5123\u20135125. doi: 10.1016/j.bmcl.2008.07.099.", "ArticleIdList": ["10.1016/j.bmcl.2008.07.099", "18710805"]}, {"Citation": "Arita M., Wakita T., Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. Pt 10J. Gen. Virol. 2008;89:2518\u20132530. doi: 10.1099/vir.0.2008/002915-0.", "ArticleIdList": ["10.1099/vir.0.2008/002915-0", "18796721"]}, {"Citation": "Meselhy M.R. Inhibition of LPS-induced NO production by the oleogum resin of Commiphora wightii and its constituents. Phytochemistry. 2003;62:213\u2013218. doi: 10.1016/S0031-9422(02)00388-6.", "ArticleIdList": ["10.1016/S0031-9422(02)00388-6", "12482459"]}, {"Citation": "Dias D.A., Urban S. Phytochemical investigation of the Australian lichens Ramalina glaucescens and Xanthoria parietina. Nat. Prod. Commun. 2009;4:959\u2013964. doi: 10.1177/1934578X0900400717.", "ArticleIdList": ["10.1177/1934578X0900400717", "19731602"]}, {"Citation": "Lee H.S., Lee B.W., Kim M.R., Jun J.G. Syntheses of Resveratrol and its Hydroxylated Derivatives as Radical Scavenger and Tyrosinase Inhibitor. Bull. Korean Chem. Soc. 2010;31:971\u2013975. doi: 10.5012/bkcs.2010.31.04.971.", "ArticleIdList": ["10.5012/bkcs.2010.31.04.971"]}, {"Citation": "Commodari F., Khiat A., Ibrahimi S., Brizius A.R., Kalkstein N. Comparison of the phytoestrogen trans-resveratrol (3,4\u2032,5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn. Reson. Chem. 2005;43:567\u2013572. doi: 10.1002/mrc.1583.", "ArticleIdList": ["10.1002/mrc.1583", "15809979"]}, {"Citation": "Kubo I., Murai Y., Soediro I., Soetarno S., Sastrodihardjo S. Cytotoxic anthraquinones from Rheum pulmatum. Phytochemistry. 1992;31:1063\u20131065. doi: 10.1016/0031-9422(92)80078-S.", "ArticleIdList": ["10.1016/0031-9422(92)80078-S"]}, {"Citation": "Dai L.-M., Tang J., Li H.-L., Shen Y.-H., Peng C.-Y., Zhang W.-D. A new stilbene glycoside from the n-butanol fraction of Veratrum dahuricum. Chem. Nat. Compd. 2009;45:325\u2013329. doi: 10.1007/s10600-009-9352-8.", "ArticleIdList": ["10.1007/s10600-009-9352-8"]}, {"Citation": "Ngoc T.M., Hung T.M., Thuong P.T., Na M., Kim H., Ha D.T., Min B.-S., Minh P.T.H., Bae K. Inhibition of Human Low Density Lipoprotein and High Density Lipoprotein Oxidation by Oligostilbenes from Rhubarb. Biol. Pharm. Bull. 2008;31:1809\u20131812. doi: 10.1248/bpb.31.1809.", "ArticleIdList": ["10.1248/bpb.31.1809", "18758083"]}, {"Citation": "Pezet R., Perret C., Jean-Denis J.B., Tabacchi R., Gindro K., Viret O. Delta-viniferin, a resveratrol dehydrodimer: One of the major stilbenes synthesized by stressed grapevine leaves. J. Agric. Food Chem. 2003;51:5488\u20135492. doi: 10.1021/jf030227o.", "ArticleIdList": ["10.1021/jf030227o", "12926902"]}, {"Citation": "Semple S.J., Pyke S.M., Reynolds G.D., Flower R.L. In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus. Antiviral Res. 2001;49:169\u2013178. doi: 10.1016/S0166-3542(01)00125-5.", "ArticleIdList": ["10.1016/S0166-3542(01)00125-5", "11428243"]}, {"Citation": "Kiem P.V., Nhiem N.X., Cuong N.X., Hoa T.Q., Huong H.T., Huong L.M., Minh C.V., Kim Y.H. New phenylpropanoid esters of sucrose from Polygonum hydropiper and their antioxidant activity. Arch. Pharm. Res. 2008;31:1477\u20131482. doi: 10.1007/s12272-001-2133-y.", "ArticleIdList": ["10.1007/s12272-001-2133-y", "19023545"]}, {"Citation": "Ridgway N.D., Dawson P.A., Ho Y.K., Brown M.S., Goldstein J.L. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. J. Cell Biol. 1992;116:307\u2013319. doi: 10.1083/jcb.116.2.307.", "ArticleIdList": ["10.1083/jcb.116.2.307", "PMC2289278", "1730758"]}, {"Citation": "Kobayashi J., Arita M., Sakai S., Kojima H., Senda M., Senda T., Hanada K., Kato R. Ligand Recognition by the Lipid Transfer Domain of Human OSBP Is Important for Enterovirus Replication. ACS Infect. Dis. 2022;8:1161\u20131170. doi: 10.1021/acsinfecdis.2c00108.", "ArticleIdList": ["10.1021/acsinfecdis.2c00108", "35613096"]}, {"Citation": "Torney H.L., Dulworth J.K., Steward D.L. Antiviral activity and mechanism of action of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) Antimicrob. Agents Chemother. 1982;22:635\u2013638. doi: 10.1128/AAC.22.4.635.", "ArticleIdList": ["10.1128/AAC.22.4.635", "PMC183805", "7181474"]}, {"Citation": "Ishitsuka H., Ohsawa C., Ohiwa T., Umeda I., Suhara Y. Antipicornavirus flavone Ro 09-0179. Antimicrob. Agents Chemother. 1982;22:611\u2013616. doi: 10.1128/AAC.22.4.611.", "ArticleIdList": ["10.1128/AAC.22.4.611", "PMC183801", "6295260"]}, {"Citation": "Galabov A.S., Nikolaeva L., Philipov S. Aporphinoid alkaloid glaucinone: A selective inhibitor of poliovirus replication. Antiviral. Res. 1995;26((Suppl. 1)):A347. doi: 10.1016/0166-3542(95)94930-Z.", "ArticleIdList": ["10.1016/0166-3542(95)94930-Z"]}, {"Citation": "Nikolaeva-Glomb L., Philipov S., Galabov A.S. Oxoglaucin\u2014Enterovirus replication inhibitor: Study on the antiviral spectrum, mode of action and development of resistance (in Bulgarian) J. Bulg. Acad. Sci. 2007;120:22\u201326."}, {"Citation": "Wang J., Zhang T., Du J., Cui S., Yang F., Jin Q. Anti-enterovirus 71 effects of chrysin and its phosphate ester. PLoS ONE. 2014;9:e89668. doi: 10.1371/journal.pone.0089668.", "ArticleIdList": ["10.1371/journal.pone.0089668", "PMC3943725", "24598537"]}, {"Citation": "Gunaseelan S., Wong K.Z., Min N., Sun J., Ismail N., Tan Y.J., Lee R.C.H., Chu J.J.H. Prunin suppresses viral IRES activity and is a potential candidate for treating enterovirus A71 infection. Sci. Transl. Med. 2019;11:eaar5759. doi: 10.1126/scitranslmed.aar5759.", "ArticleIdList": ["10.1126/scitranslmed.aar5759", "31666401"]}, {"Citation": "Zhang H.M., Wang F., Qiu Y., Ye X., Hanson P., Shen H., Yang D. Emodin inhibits coxsackievirus B3 replication via multiple signalling cascades leading to suppression of translation. Biochem. J. 2016;473:473\u2013485. doi: 10.1042/BJ20150419.", "ArticleIdList": ["10.1042/BJ20150419", "26621875"]}, {"Citation": "Zhong T., Zhang L.Y., Wang Z.Y., Wang Y., Song F.M., Zhang Y.H., Yu J.H. Rheum emodin inhibits enterovirus 71 viral replication and affects the host cell cycle environment. Acta Pharmacol. Sin. 2017;38:392\u2013401. doi: 10.1038/aps.2016.110.", "ArticleIdList": ["10.1038/aps.2016.110", "PMC5342659", "27840410"]}, {"Citation": "Nugent C.I., Johnson K.L., Sarnow P., Kirkegaard K. Functional coupling between replication and packaging of poliovirus replicon RNA. J. Virol. 1999;73:427\u2013435. doi: 10.1128/JVI.73.1.427-435.1999.", "ArticleIdList": ["10.1128/JVI.73.1.427-435.1999", "PMC103849", "9847348"]}, {"Citation": "Arita M. High-Order Epistasis and Functional Coupling of Infection Steps Drive Virus Evolution toward Independence from a Host Pathway. Microbiol. Spectr. 2021;9:e0080021. doi: 10.1128/Spectrum.00800-21.", "ArticleIdList": ["10.1128/Spectrum.00800-21", "PMC8557862", "34468191"]}, {"Citation": "Buontempo P.J., Cox S., Wright-Minogue J., DeMartino J.L., Skelton A.M., Ferrari E., Albin R., Rozhon E.J., Girijavallabhan V., Modlin J.F., et al. SCH 48973: A potent, broad-spectrum, antienterovirus compound. Antimicrob. Agents Chemother. 1997;41:1220\u20131225. doi: 10.1128/AAC.41.6.1220.", "ArticleIdList": ["10.1128/AAC.41.6.1220", "PMC163890", "9174174"]}, {"Citation": "Oberste M.S., Moore D., Anderson B., Pallansch M.A., Pevear D.C., Collett M.S. In vitro antiviral activity of V-073 against polioviruses. Antimicrob. Agents Chemother. 2009;53:4501\u20134503. doi: 10.1128/AAC.00671-09.", "ArticleIdList": ["10.1128/AAC.00671-09", "PMC2764203", "19635956"]}, {"Citation": "Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., Petersen A., Smith G.J., 3rd, Zalman L.S., Burns-Naas L.A., et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2005;49:2267\u20132275. doi: 10.1128/AAC.49.6.2267-2275.2005.", "ArticleIdList": ["10.1128/AAC.49.6.2267-2275.2005", "PMC1140523", "15917520"]}, {"Citation": "Rhoden E., Liu H.M., Wang-Chern S.W., Oberste M.S. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res. 2013;98:186\u2013191. doi: 10.1016/j.antiviral.2013.03.003.", "ArticleIdList": ["10.1016/j.antiviral.2013.03.003", "23499651"]}, {"Citation": "Kankam M.K., Burns J.M., Collett M.S., Corrado M.L., Hincks J.R. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers. Antimicrob. Agents Chemother. 2021;65:e0102921. doi: 10.1128/AAC.01029-21.", "ArticleIdList": ["10.1128/AAC.01029-21", "PMC8448163", "34370575"]}, {"Citation": "McKinlay M.A., Collett M.S., Hincks J.R., Oberste M.S., Pallansch M.A., Okayasu H., Sutter R.W., Modlin J.F., Dowdle W.R. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J. Infect. Dis. 2014;210((Suppl. 1)):S447\u2013S453. doi: 10.1093/infdis/jiu043.", "ArticleIdList": ["10.1093/infdis/jiu043", "25316866"]}, {"Citation": "WHO.  [(accessed on 27 February 2023)].  Available online:  https://polioeradication.org/tools-and-library/current-research-areas/antivirals/"}, {"Citation": "Zimmermann M.L., Sneden A.T. Vanicosides A and B, protein kinase C inhibitors from Polygonum pensylvanicum. J. Nat. Prod. 1994;57:236\u2013242. doi: 10.1021/np50104a007.", "ArticleIdList": ["10.1021/np50104a007", "8176400"]}, {"Citation": "Ahmad R., Sahidin I., Taher M., Low C., Noor N.M., Sillapachaiyaporn C., Chuchawankul S., Sarachana T., Tencomnao T., Iskandar F., et al. Polygonumins A, a newly isolated compound from the stem of Polygonum minus Huds with potential medicinal activities. Sci. Rep. 2018;8:4202. doi: 10.1038/s41598-018-22485-5.", "ArticleIdList": ["10.1038/s41598-018-22485-5", "PMC5845017", "29523802"]}, {"Citation": "Nawrot-Hadzik I., Zmudzinski M., Matkowski A., Preissner R., Kesik-Brodacka M., Hadzik J., Drag M., Abel R. Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors-Molecular Docking and In Vitro Study. Pharmaceuticals. 2021;14:742. doi: 10.3390/ph14080742.", "ArticleIdList": ["10.3390/ph14080742", "PMC8399519", "34451839"]}, {"Citation": "Arita M. Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure. Microbiol. Immunol. 2014;58:239\u2013256. doi: 10.1111/1348-0421.12144.", "ArticleIdList": ["10.1111/1348-0421.12144", "24527995"]}, {"Citation": "Arita M. Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III \u03b2 Inhibitor. ACS Infect. Dis. 2016;2:140\u2013148. doi: 10.1021/acsinfecdis.5b00122.", "ArticleIdList": ["10.1021/acsinfecdis.5b00122", "27624965"]}, {"Citation": "Lyoo H., Dorobantu C.M., van der Schaar H.M., van Kuppeveld F.J.M. Modulation of proteolytic polyprotein processing by coxsackievirus mutants resistant to inhibitors targeting phosphatidylinositol-4-kinase IIIbeta or oxysterol binding protein. Antiviral Res. 2017;147:86\u201390. doi: 10.1016/j.antiviral.2017.10.006.", "ArticleIdList": ["10.1016/j.antiviral.2017.10.006", "29024767"]}, {"Citation": "Melia C.E., van der Schaar H.M., Lyoo H., Limpens R., Feng Q., Wahedi M., Overheul G.J., van Rij R.P., Snijder E.J., Koster A.J., et al. Escaping Host Factor PI4KB Inhibition: Enterovirus Genomic RNA Replication in the Absence of Replication Organelles. Cell Rep. 2017;21:587\u2013599. doi: 10.1016/j.celrep.2017.09.068.", "ArticleIdList": ["10.1016/j.celrep.2017.09.068", "PMC5656745", "29045829"]}, {"Citation": "Lamarche M.J., Borawski J., Bose A., Capacci-Daniel C., Colvin R., Dennehy M., Ding J., Dobler M., Drumm J., Gaither L.A., et al. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 2012;56:5149\u20135156. doi: 10.1128/AAC.00946-12.", "ArticleIdList": ["10.1128/AAC.00946-12", "PMC3457382", "22825118"]}, {"Citation": "Spickler C., Lippens J., Laberge M.K., Desmeules S., Bellavance E., Garneau M., Guo T., Hucke O., Leyssen P., Neyts J., et al. Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal Phenotype In Vivo. Antimicrob. Agents Chemother. 2013;57:3358\u20133368. doi: 10.1128/AAC.00303-13.", "ArticleIdList": ["10.1128/AAC.00303-13", "PMC3697394", "23650168"]}, {"Citation": "Matsui T., Fujita M., Ishibashi Y., Nomanbhoy T., Rosenblum J.S., Nagasawa M. 134. KRP-A218, an Orally Active and Selective PI4KB Inhibitor with Broad-Spectrum Anti-Rhinovirus Activity, Has Potent Therapeutic Antiviral Activity In Vivo. Open Forum Infect. Dis. 2021;8((Suppl. 1)):S82. doi: 10.1093/ofid/ofab466.134.", "ArticleIdList": ["10.1093/ofid/ofab466.134"]}, {"Citation": "Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733\u2013747. doi: 10.1016/j.cell.2006.03.035.", "ArticleIdList": ["10.1016/j.cell.2006.03.035", "PMC2946820", "16647110"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "2", "Day": "27"}, {"Year": "2023", "Month": "3", "Day": "29"}, {"Year": "2023", "Month": "3", "Day": "30"}, {"Year": "2023", "Month": "5", "Day": "1", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "4", "Day": "28", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "4", "Day": "28", "Hour": "1", "Minute": "54"}, {"Year": "2023", "Month": "3", "Day": "31"}], "PublicationStatus": "epublish", "ArticleIdList": ["37112883", "PMC10145814", "10.3390/v15040903", "v15040903"]}}], "PubmedBookArticle": []}